This invention relates to compounds of formula I wherein RSUP1 /SUPand RSUP2 /SUPare defined herein, or a pharmaceutically acceptable salt thereof. It has been found that the compounds of formula I are adenosine receptor ligands with good affinity to the ASUB2A/SUB-receptor and a high selectivity to the ASUB1/SUB- and ASUB3 /SUBreceptors. These compounds are useful, inter alia, in treatment of Alzheimer's disease, depression, Parkinson's disease and ADHD.
展开▼